Compare QTWO & IDYA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | QTWO | IDYA |
|---|---|---|
| Founded | 2004 | 2015 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Computer Software: Prepackaged Software | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 3.1B | 2.9B |
| IPO Year | 2014 | 2019 |
| Metric | QTWO | IDYA |
|---|---|---|
| Price | $51.73 | $33.92 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 11 | 16 |
| Target Price | ★ $82.64 | $52.86 |
| AVG Volume (30 Days) | 532.4K | ★ 1.5M |
| Earning Date | 04-29-2026 | 05-05-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 225.00 | 61.90 |
| EPS | ★ 0.80 | N/A |
| Revenue | $193,978,000.00 | ★ $218,710,000.00 |
| Revenue This Year | $12.48 | N/A |
| Revenue Next Year | $10.18 | $201.05 |
| P/E Ratio | $63.73 | ★ N/A |
| Revenue Growth | N/A | ★ 3024.43 |
| 52 Week Low | $44.65 | $16.81 |
| 52 Week High | $95.10 | $39.28 |
| Indicator | QTWO | IDYA |
|---|---|---|
| Relative Strength Index (RSI) | 60.09 | 56.21 |
| Support Level | $45.18 | $32.85 |
| Resistance Level | $52.02 | $34.76 |
| Average True Range (ATR) | 1.87 | 2.12 |
| MACD | 0.73 | 0.21 |
| Stochastic Oscillator | 90.89 | 44.01 |
Q2 Holdings Inc provides digital solutions to financial institutions, financial technology companies, and alternative finance companies, seeking to incorporate banking into their customer engagement and servicing strategies. The company helps its clients with supervisory, consumer protection, privacy, third-party risk management requirements, and cyber threats and fraud, among other applications, by offering a portfolio of digital solutions, which comprises its digital banking offerings, digital lending and relationship pricing solutions, risk and fraud solutions, as well as Q2 Innovation Studio and Helix. Q2 derives the majority of its revenue from subscription fees for the use of its hosted solutions.
IDEAYA Biosciences Inc is an oncology-focused precision medicine company committed to the discovery and development of targeted therapeutics for patient populations selected using molecular diagnostics. Its approach integrates small molecule drug discovery with extensive capabilities in identifying and validating translational biomarkers to develop targeted therapies for select patient populations that are likely to benefit from these targeted therapies. The company's clinical-stage product candidates include darovasertib (PKC), IDE397 (MAT2A), IDE849 (DLL3), IDE275 (Werner Helicase), IDE161 (PARG), and IDE705 (Pol Theta Helicase). In addition, it also working on other development candidates and has multiple earlier-stage preclinical programs.